Tibet Cheezheng Tibetan Medicine Past Earnings Performance
Past criteria checks 3/6
Tibet Cheezheng Tibetan Medicine has been growing earnings at an average annual rate of 5.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 10.5% per year. Tibet Cheezheng Tibetan Medicine's return on equity is 15.2%, and it has net margins of 26.2%.
Key information
5.9%
Earnings growth rate
5.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 10.5% |
| Return on equity | 15.2% |
| Net Margin | 26.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tibet Cheezheng Tibetan Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,271 | 594 | 1,279 | 60 |
| 30 Jun 24 | 2,225 | 595 | 1,267 | 59 |
| 31 Mar 24 | 2,114 | 586 | 1,186 | 61 |
| 31 Dec 23 | 2,045 | 581 | 1,162 | 59 |
| 30 Sep 23 | 1,875 | 494 | 1,075 | 48 |
| 30 Jun 23 | 1,978 | 552 | 1,070 | 52 |
| 31 Mar 23 | 1,933 | 478 | 1,093 | 51 |
| 01 Jan 23 | 2,045 | 473 | 1,107 | 55 |
| 30 Sep 22 | 1,993 | 429 | 1,083 | 73 |
| 30 Jun 22 | 1,881 | -40 | 1,045 | 73 |
| 31 Mar 22 | 1,849 | 700 | 1,027 | 72 |
| 01 Jan 22 | 1,770 | 716 | 985 | 71 |
| 30 Sep 21 | 1,657 | 727 | 894 | 67 |
| 30 Jun 21 | 1,659 | 1,171 | 880 | 68 |
| 31 Mar 21 | 1,662 | 458 | 911 | 67 |
| 31 Dec 20 | 1,485 | 404 | 829 | 60 |
| 30 Sep 20 | 1,454 | 413 | 830 | 64 |
| 30 Jun 20 | 1,405 | 383 | 838 | 57 |
| 31 Mar 20 | 1,301 | 328 | 769 | 56 |
| 31 Dec 19 | 1,403 | 364 | 824 | 56 |
| 30 Sep 19 | 1,328 | 348 | 768 | 45 |
| 30 Jun 19 | 1,281 | 331 | 740 | 46 |
| 31 Mar 19 | 1,240 | 326 | 719 | 39 |
| 01 Jan 19 | 1,213 | 319 | 697 | 37 |
| 30 Sep 18 | 1,218 | 339 | 684 | 32 |
| 30 Jun 18 | 1,137 | 321 | 621 | 34 |
| 31 Mar 18 | 1,086 | 309 | 593 | 30 |
| 31 Dec 17 | 1,053 | 301 | 580 | 26 |
| 30 Sep 17 | 1,018 | 297 | 580 | 15 |
| 30 Jun 17 | 987 | 298 | 567 | 0 |
| 31 Mar 17 | 971 | 294 | 552 | 0 |
| 31 Dec 16 | 968 | 290 | 548 | 0 |
| 30 Sep 16 | 986 | 279 | 538 | 0 |
| 30 Jun 16 | 984 | 274 | 532 | 0 |
| 31 Mar 16 | 1,009 | 274 | 541 | 0 |
| 31 Dec 15 | 995 | 265 | 529 | 0 |
| 30 Sep 15 | 984 | 252 | 493 | 0 |
| 30 Jun 15 | 1,009 | 259 | 472 | 0 |
| 31 Mar 15 | 979 | 243 | 459 | 0 |
| 31 Dec 14 | 950 | 238 | 452 | 0 |
| 30 Sep 14 | 923 | 234 | 405 | 0 |
| 30 Jun 14 | 906 | 229 | 387 | 0 |
| 31 Mar 14 | 907 | 218 | 373 | 0 |
| 31 Dec 13 | 969 | 213 | 378 | 0 |
Quality Earnings: 002287 has a large one-off gain of CN¥228.8M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 002287's current net profit margins (26.2%) are lower than last year (26.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002287's earnings have grown by 5.9% per year over the past 5 years.
Accelerating Growth: 002287's earnings growth over the past year (20.4%) exceeds its 5-year average (5.9% per year).
Earnings vs Industry: 002287 earnings growth over the past year (20.4%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 002287's Return on Equity (15.2%) is considered low.